About Masimo Corporation:
Masimo (Nasdaq:MASI) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. Masimo's IPO was one of the most successful IPOs of 2007 and 2008, and was the top medical device IPO over the same period.
Masimo's success comes from innovation. Recently, Masimo introduced its latest breakthrough technology -- the first-and-only FDA-cleared technology that noninvasively and continuously measures total hemoglobin-without a painful needle stick and invasive blood draw. Masimo noninvasive total hemoglobin monitoring delivers significant benefits to patients and healthcare professionals by enabling earlier and better clinical decision-making, improved patient safety, and reduced costs.
In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring platform that measures many blood constituents that previously required invasive procedures. Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(tm)), oxygen content (SpOC(tm)), carboxyhemoglobin (SpCO(r)), methemoglobin (SpMet(r)), and PVI(tm), in addition to oxyhemoglobin (SpO2), perfusion index (PI) and pulse rate.
Founded in 1989, Masimo is focused on its mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications."
For more information about the Masimo Corporation [MASI] , please visit www.masimo.com.
| Copyright | Disclaimer | Trademarks | Privacy Statement | Contact Us | Help | Search |
